# Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis

> **NCT02722447** · PHASE3 · UNKNOWN · sponsor: **Walter Ageno** · enrollment: 1100 (estimated)

## Conditions studied

- Deep Vein Thrombosis

## Interventions

- **DRUG:** rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02722447
- **Lead sponsor:** Walter Ageno
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2019-06
- **Final completion:** 2021-06
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722447, "Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02722447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*